Pliant Therapeutics Q3 net loss $57.8M; BEACON-IPF enrollment on track for Q1 2025

PLIANT THERAPEUTICS, INC.

2024-Q3 EPS reported -$2.66

Net loss of $57.8M vs $41.5M in Q3 2023; R&D expenses rose to $47.8M on BEACON-IPF trial.
Cash and investments of $406.0M as of Sept 30, 2024; no revenue reported.
BEACON-IPF Phase 2b/3 trial enrolling well; full enrollment expected Q1 2025, data mid-2026.
Phase 1 trial of PLN-101095 in solid tumors dosing third cohort; preliminary data early 2025.
Gary Palmer appointed SVP of Medical Affairs; brings 25+ years from Bristol Myers Squibb.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.